Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0BI3K
|
|||
| Drug Name |
Omburtamab I-124
|
|||
| Indication | Glioma [ICD-11: 2A00.0; ICD-9: 191] | Phase 1/2 | [1], [2] | |
| Company |
Y-mAbs Therapeutics New York, NY
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B7 homolog 3 (CD276) | Target Info | Inhibitor | [1], [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.